Could Aurinia Pharmaceuticals Inchares (NASDAQ:AUPH) Go Down After Its Newest Short Interest Report?

October 2, 2018 - By Ruchi Gupta

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Logo

The stock of Aurinia Pharmaceuticals Inchares (NASDAQ:AUPH) registered a decrease of 4.71% in short interest. AUPH’s total short interest was 8.12M shares in October as published by FINRA. Its down 4.71% from 8.52 million shares, reported previously. With 385,700 shares average volume, it will take short sellers 21 days to cover their AUPH’s short positions. The short interest to Aurinia Pharmaceuticals Inchares’s float is 16.99%.

The stock increased 3.03% or $0.19 during the last trading session, reaching $6.46. About 607,879 shares traded or 29.73% up from the average. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has declined 14.58% since October 2, 2017 and is downtrending. It has underperformed by 30.20% the S&P500.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $543.29 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.

More important recent Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) news were published by: Seekingalpha.com which released: “2018 Is An Ideal Entry Point For Aurinia Pharmaceuticals” on September 10, 2018, also Streetinsider.com published article titled: “Aurinia Pharmaceuticals (AUPH) Reports Complete Enrollment of AURORA Phase 3 Clinical Trial for Treatment of Lupus”, Seekingalpha.com published: “Aurinia completes enrollment of AURORA for the treatment of Lupus Nephritis” on September 26, 2018. More interesting news about Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) was released by: Benzinga.com and their article: “The Daily Biotech Pulse: Verastem’s Chinese Duvelisib Licensing Deal, Aldeyra’s Positive Dry Eye Disease Drug Trial” with publication date: September 26, 2018.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>